Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA:600196)
23.89
+0.13 (0.55%)
Oct 9, 2026, 3:00 PM CST
SHA:600196 Revenue
Shanghai Fosun Pharmaceutical (Group) had revenue of 10.37B CNY in the quarter ending June 30, 2026, with 2.72% growth. This brings the company's revenue in the last twelve months to 42.59B, up 6.16% year-over-year. In the year 2025, Shanghai Fosun Pharmaceutical (Group) had annual revenue of 41.66B with 1.45% growth. That makes Shanghai Fosun Pharmaceutical (Group) the 2,157th largest company in the world by revenue and 235th in China.
Revenue (ttm)
42.59B
Revenue Growth
+6.16%
P/S Ratio
1.37
Revenue / Employee
1.05M
Employees
40,684
Market Cap
58.39B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 41.66B | 594.42M | 1.45% |
| Dec 31, 2024 | 41.07B | -332.34M | -0.80% |
| Dec 31, 2023 | 41.40B | -2.55B | -5.81% |
| Dec 31, 2022 | 43.95B | 4.94B | 12.66% |
| Dec 31, 2021 | 39.01B | 8.70B | 28.72% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Huadong Medicine | 44.00B |
| Yunnan Baiyao Group Co.,Ltd | 41.81B |
| China Resources Sanjiu Medical & Pharmaceutical | 31.81B |
| Zhejiang NHU Company | 24.28B |
| Humanwell Healthcare (Group) | 23.96B |
| Beijing Tongrentang | 15.87B |
| Changchun High-Tech Industry (Group) | 11.02B |
| Apeloa Pharmaceutical Co.,Ltd | 9.16B |
Shanghai Fosun Pharmaceutical (Group) News
- 11 days ago - India's Sun Pharma plans $1 billion local debt sale for loan takeout, sources say - Reuters
- 4 weeks ago - Fosun Pharma Announces H-Share Repurchase Plan of Up to HK$ 1 Billion - PRNewsWire
- 6 weeks ago - Fosun Pharma Announces 2026 Interim Results - PRNewsWire
- 6 weeks ago - Shanghai Fosun Pharmaceutical (Group) Quarterly report: Q2 2026 - Filings
- 5 months ago - Shanghai Fosun Pharmaceutical (Group) Quarterly report: Q1 2026 - Filings
- 6 months ago - Global pharma companies that have publicly announced Trump drug pricing agreements - Reuters
- 6 months ago - Shanghai Fosun Pharmaceutical (Group) Annual report: H2 2025 - Filings
- 6 months ago - Shanghai Fosun Pharmaceutical (Group) Slides: H2 2025 - Filings